Media stories about Spark Therapeutics (NASDAQ:ONCE) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.0953393059643 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Spark Therapeutics, Inc. (ONCE) CFO Sells $701,400.00 in Stock (americanbankingnews.com)
- $1 million price tag in spotlight as gene therapy becomes reality (finance.yahoo.com)
- Spark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- BMO Capital Markets Reiterates Buy Rating for Spark Therapeutics, Inc. (ONCE) (americanbankingnews.com)
- Oversold Conditions For Spark Therapeutics (ONCE) – Nasdaq (nasdaq.com)
Several equities research analysts recently issued reports on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $89.00 price target (up from $69.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $100.00 in a research report on Tuesday, August 8th. SunTrust Banks, Inc. set a $101.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, October 16th. Cowen and Company restated an “outperform” rating and set a $95.00 price objective (up from $75.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Finally, Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $90.36.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.07) earnings per share. research analysts predict that Spark Therapeutics will post -7.6 EPS for the current fiscal year.
In other Spark Therapeutics news, insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $80.25, for a total transaction of $802,500.00. Following the sale, the insider now owns 220,000 shares of the company’s stock, valued at $17,655,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total transaction of $84,630,000.00. Following the sale, the director now directly owns 3,928,707 shares in the company, valued at approximately $332,486,473.41. The disclosure for this sale can be found here. Insiders sold 1,109,659 shares of company stock valued at $93,159,058 over the last 90 days. 7.30% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/21/spark-therapeutics-once-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
What are top analysts saying about Spark Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc. and related companies.